Multi-omics Profiling Uncovers Predictive Factors for Tumor-Infiltrating Lymphocyte Therapy in Ovarian Cancer

Background: Ovarian cancer (OC) remains a challenging malignancy with poor prognosis, particularly in advanced stages. Tumor-infiltrating lymphocyte (TIL) therapy shows promise but has yielded inconsistent results in OC patients. This study aimed to identify factors predicting successful TIL isolation and expansion in OC. Methods: We performed multi-omics profiling on tumor samples from 10 OC patients, including whole-exome sequencing, bulk RNA sequencing, and single-cell RNA sequencing. Dataset: Bulk RNA-seq of OC tumor samplles and single-cell profiling of tumors yielding successful TIL products (TIL+) versus those that did not (TIL-), and two round of ex vivo TIL expansions. Conclusion: Our findings provide insights into factors affecting TIL therapy efficacy in OC and suggest potential strategies for optimizing patient selection and TIL manufacturing protocols.背景：卵巢癌（Ovarian cancer, OC）仍是一类预后不佳的难治性恶性肿瘤，晚期患者的治疗困境尤为突出。肿瘤浸润淋巴细胞（Tumor-infiltrating lymphocyte, TIL）疗法展现出临床应用潜力，但在卵巢癌患者中却呈现出不一致的治疗效果。本研究旨在明确可预测卵巢癌患者TIL分离与扩增成功的相关因素。 方法：本研究对10名卵巢癌患者的肿瘤样本开展多组学分析，涵盖全外显子组测序、批量RNA测序及单细胞RNA测序。 数据集：包含卵巢癌肿瘤样本的批量RNA测序数据，以及获得成功肿瘤浸润淋巴细胞产物的肿瘤样本（TIL+组）与未获得该产物的肿瘤样本（TIL-组）的单细胞分析数据，同时涵盖两轮离体肿瘤浸润淋巴细胞扩增的相关数据。 结论：本研究结果为阐明影响卵巢癌患者TIL疗法疗效的相关因素提供了科学见解，并为优化患者筛选流程及TIL制备方案提供了潜在策略。